Among GLP-1 RAs, liraglutide (from 1.2 mg/day to 1.8 mg/day subcutaneously) and semaglutide (from 0.25 mg/week to 2.4 mg/week subcutaneously or from 3 mg/day to 14 mg/day orally) are approved not only for the treatment of type 2 diabetes mellitus but also for the treatment of obesity [11]. Here, GLP1R is linked to obesity disorder.